Home » Stocks » VXRT

Vaxart, Inc. (VXRT)

Stock Price: $7.20 USD 0.27 (3.90%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $7.15 -0.05 (-0.69%) May 7, 7:59 PM
Market Cap 849.34M
Revenue (ttm) 1.65M
Net Income (ttm) -46.93M
Shares Out 117.96M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE 45.87
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $7.20
Previous Close $6.93
Change ($) 0.27
Change (%) 3.90%
Day's Open 6.76
Day's Range 6.70 - 7.46
Day's Volume 11,763,217
52-Week Range 2.23 - 24.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Here's how the biotechs compare on several key fronts.

Other stocks mentioned: OCGN
1 day ago - The Motley Fool

If it can reach the market of people that are hesitant to be vaccinated, yes.

2 days ago - The Motley Fool

Its coronavirus vaccine candidate may stand out, if upcoming trials are successful.

2 days ago - The Motley Fool

Investors are excited about the company's experimental COVID-19 vaccine.

3 days ago - The Motley Fool

The shares of biotechnology concern Vaxart Inc (NASDAQ:VXRT) are up a whopping 11.5% to trade at $8.94 at last check , after the company announced its oral coronavirus vaccine produced positive phase 1 ...

3 days ago - Schaeffers Research

Shareholders keep getting their hopes up for the company's tablet-based COVID-19 vaccine.

3 days ago - The Motley Fool

Vaxart Inc (NASDAQ: VXRT) has announced new data from the Phase 1 trial evaluating its oral COVID-19 vaccine candidate, dubbed as VXA-CoV2-1. Data obtained showed substantial CD8+ T-cell responses again...

4 days ago - Benzinga

Vaxart oral vaccine induced higher CD8 + T-Cell responses than those seen with  Moderna or Pfizer vaccines in comparative experiment conducted by the Company

4 days ago - GlobeNewsWire

Ocugen Inc. (NASDAQ: OCGN) and Vaxart Inc. (NASDAQ: VXRT) are moving Monday. Ocugen shares gapped higher after the company's studies showed that COVAXIN is potentially effective against three key varian...

Other stocks mentioned: OCGN
4 days ago - Benzinga

VAXART, INC. (VXRT) delivered earnings and revenue surprises of -40.00% and -17.99%, respectively, for the quarter ended March 2021.

4 days ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by room-temperature stabl...

5 days ago - GlobeNewsWire

The biotech is slated to provide updates to investors on its vaccine development efforts next week.

1 week ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet r...

1 week ago - GlobeNewsWire

VXRT stock is up huge today as the company announces a coming webinar. Investors are turning bullish as they expect to hear promising news.

1 week ago - InvestorPlace

Vaxart Inc. (NASDAQ:VXRT) shares are trading sharply higher Tuesday after the stock was trending on StockTwits. On Monday, the company announced it will host a key opinion leader webinar on the importan...

1 week ago - Benzinga

Many people want to be vaccinated, but hardly anybody likes injections. Soon VXRT stock could surge as Vaxart offers a less invasive method.

1 week ago - InvestorPlace

These tiny stocks could pack big-time return potential, if analysts are correct.

Other stocks mentioned: EVER, HRVSF, INO, JUSHF
1 week ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet r...

2 weeks ago - GlobeNewsWire

Analysts' consensus price targets imply that these stocks can more than double over the next 12 months.

Other stocks mentioned: ICPT, NKLA, PLUG, SKLZ
2 weeks ago - The Motley Fool

It's a gamble, but the payoff might be worth the risk.

3 weeks ago - The Motley Fool

Both could play important roles in the future vaccine landscape.

Other stocks mentioned: NVAX
1 month ago - The Motley Fool

Sometimes, the huge potential gains of small biotechs are worth the risk.

Other stocks mentioned: JNJ, SNY
1 month ago - The Motley Fool

Vaxart stock has declined by around 25% over the last month and currently trades at about $5.80 per share. While the recent sell-off in the clinical stage biotech is due to broader correction in technol...

1 month ago - Forbes

Let's look at what some of the smartest investors are saying.

Other stocks mentioned: INO
1 month ago - The Motley Fool

Vaxart Inc. (NASDAQ: VXRT) shares gained 2.69% Tuesday on increased volume, closing the session at $7.06.  The stock was trending on StockTwits, and there was no company evident news to explain the volu...

1 month ago - Benzinga

Each of these players has dropped about 40% or more in recent weeks.

Other stocks mentioned: JNJ, MRNA, NVAX, OCGN, PFE
1 month ago - The Motley Fool

If its oral vaccine technology comes to fruition, then answering that question is easy.

1 month ago - The Motley Fool

Vaxart stock dropped 16% over the last five trading days, significantly underperforming the S&P 500 which gained about 1% over the same period. The stock is also down by about 40% over the last month (t...

1 month ago - Forbes

A flaw in the logic behind a big sell-off may lead to a big surprise sometime in 2021.

2 months ago - The Motley Fool

The clinical-stage vaccine-focused biotech recently offered investors a glimmer of hope about its COVID-19 candidate.

2 months ago - The Motley Fool

And let's take a look at the most overrated, the most promising, and the most under-the-radar coronavirus stocks too.

Other stocks mentioned: NVAX, OCGN, PFE
2 months ago - The Motley Fool

Vaxart's trial data disappointed -- but one bright spot could turn things around.

2 months ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet r...

2 months ago - GlobeNewsWire

There are plenty of entrants in the race to develop a Covid-19 vaccine, but distinct advantages mark VXRT stock as a worthy biotech holding. The post Vaxart Stock Remains a Buy as Unique Covid-19 Vaccin...

2 months ago - InvestorPlace

VAXART, INC. (VXRT) witnessed a jump in share price last session on above-average trading volume.

2 months ago - Zacks Investment Research

Vaxart stock (NASDAQ: VXRT) dropped -8% over the last five trading days and has underperformed the S&P 500 which remained roughly flat over the same period. The stock is also down by about -27% over the...

2 months ago - Forbes

The short answer: maybe.

2 months ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by in...

2 months ago - GlobeNewsWire

Let's look at what short-sellers are saying and what science is saying.

2 months ago - The Motley Fool

In the latest trading session, VAXART, INC. (VXRT) closed at $6.79, marking a -0.73% move from the previous day.

2 months ago - Zacks Investment Research

VAXART, INC. (VXRT) closed the most recent trading day at $7.94, moving -1.85% from the previous trading session.

2 months ago - Zacks Investment Research

SEC 13Fs reveal trades from months ago, but also patterns of long-term bullish behavior.

Other stocks mentioned: BIGC, GME, MRNA, NVAX, SHOP
2 months ago - Zacks Investment Research

On Vaxart's (VXRT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its oral COVID-19 vaccine candidate, VXA-CoV2-1.

2 months ago - Zacks Investment Research

The choice isn't easy, but simplicity may be the answer.

Other stocks mentioned: INO
2 months ago - The Motley Fool

The company can still produce returns without a COVID vaccine.

2 months ago - The Motley Fool

The short answer: Yes.

2 months ago - The Motley Fool

Biotech company Vaxart posted mixed phase 1 results for its tablet-based Covid-19 vaccine, causing its stock to decline by over 60% from last week's high. Although the vaccine was well tolerated and pro...

2 months ago - Forbes

The once high-flying biotech stock has crashed.

2 months ago - The Motley Fool

The stock lost more than half its value in one trading session.

Other stocks mentioned: GME, MRNA, NVAX, PFE
3 months ago - The Motley Fool

Hope for an oral COVID-19 vaccine remains alive.

3 months ago - The Motley Fool

About VXRT

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, wh... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
VXRT
Full Company Profile

Financial Performance

In 2020, Vaxart's revenue was $4.05 million, a decrease of -58.97% compared to the previous year's $9.86 million. Losses were -$32.22 million, 72.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Vaxart stock is "Strong Buy." The 12-month stock price forecast is 13.33, which is an increase of 85.14% from the latest price.

Price Target
$13.33
(85.14% upside)
Analyst Consensus: Strong Buy